Aligos Therapeutics press release (ALGS): Q2 GAAP EPS of -$0.14. Cash, cash equivalents and investments totaled $30.4 million as of June 30, 2026, compared with $77.8 million as of December 31, 2025 This excludes the $25M upfront payment received from Amoytop in Jul
Aligos Therapeutics press release (ALGS): Q2 GAAP EPS of -$0.14.
Cash, cash equivalents and investments totaled $30.4 million as of June 30, 2026, compared with $77.8 million as of December 31, 2025
This excludes the $25M upfront payment received from Amoytop in July 2026. Our cash and cash equivalents
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
